ERBB2 and breast cancer: The results of the phase I trial conducted on advanced or metastatic non-small cell lung cancer (NSCLC) patients bearing EGFR-activating mutations, as well as HR-positive, HER2-negative breast cancer (BC) that had previously received third-generation tyrosine kinase inhibitors (TKIs) or CDK4/6 inhibitors and at least one line of chemotherapy were recently presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting held in Chicago.